Matching articles for "valsartan"
Issue 1757 · June 22, 2026 Free
In Brief: Widaplik — Another Three-Drug Combination for Hypertension

The FDA has approved Widaplik (Azurity), a fixed-dose combination of the angiotensin receptor blocker (ARB) telmisartan, the dihydropyridine calcium channel blocker amlodipine, and the thiazide-like diuretic…

Med Lett Drugs Ther. 2026 Jun 22; 68(1757):101-2 doi:10.58347/tml.2026.1757d
The FDA has approved Widaplik (Azurity), a fixed-dose combination of the angiotensin receptor blocker (ARB) telmisartan, the dihydropyridine calcium channel blocker amlodipine, and the thiazide-like diuretic indapamide, for treatment of hypertension in adults. Telmisartan, amlodipine, and indapamide are also available alone and in various combinations for treatment of hypertension. Two three-drug combinations containing an ARB, amlodipine, and the thiazide diuretic hydrochlorothiazide ( Exforge HCT and Tribenzor ) have been available for years (see Table 1).
Issue 1737 · September 15, 2025
A New Heart Failure Indication for Finerenone (Kerendia)

The FDA has approved the nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone (Kerendia) to reduce the risk of cardiovascular death, hospitalization for heart failure (HF), and urgent HF visits…

Med Lett Drugs Ther. 2025 Sep 15; 67(1737):146-8 doi:10.58347/tml.2025.1737b
The FDA has approved the nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone (Kerendia) to reduce the risk of cardiovascular death, hospitalization for heart failure (HF), and urgent HF visits in adults with HF with a left ventricular ejection fraction (LVEF) ≥40%. Finerenone was approved in 2021 to reduce the risk of kidney disease progression and cardiovascular events in adults with chronic kidney disease (CKD) associated with type 2 diabetes.
Issue 1729 · May 26, 2025
Drugs for Chronic Heart Failure

Pharmacologic management of chronic heart failure (HF) is primarily determined by the patient's left ventricular ejection fraction (LVEF) and severity of symptoms. Patients with chronic HF who have an LVEF…

Med Lett Drugs Ther. 2025 May 26; 67(1729):81-8 doi:10.58347/tml.2025.1729a
Pharmacologic management of chronic heart failure (HF) is primarily determined by the patient's left ventricular ejection fraction (LVEF) and severity of symptoms. Patients with chronic HF who have an LVEF ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF) and those with an LVEF ≥50% are considered to have heart failure with preserved ejection fraction (HFpEF). Patients with an LVEF of 41-49% have heart failure with mildly reduced or mid-range ejection fraction.
Issue 1729 · May 26, 2025 Free
Comparison Chart: Some Drugs for HFrEF

View the Comparison Chart: Some Drugs for HFrEF

Med Lett Drugs Ther. 2025 May 26; 67(1729):e1-15 doi:10.58347/tml.2025.1729b
View the Comparison Chart: Some Drugs for HFrEF
Issue 1703 · May 27, 2024
Drugs for Hypertension

American College of Cardiology/American Heart Association (ACC/AHA) guidelines for treatment of hypertension were last published in 2018. Treatment of hypertensive urgencies and emergencies is not discussed…

Med Lett Drugs Ther. 2024 May 27; 66(1703):81-8 doi:10.58347/tml.2024.1703a
American College of Cardiology/American Heart Association (ACC/AHA) guidelines for treatment of hypertension were last published in 2018. Treatment of hypertensive urgencies and emergencies is not discussed here.
Issue 1636 · November 1, 2021
Apoaequorin (Prevagen) to Improve Memory

A synthetic form of the protein apoaequorin is the active ingredient in the over-the-counter dietary supplement Prevagen (Quincy Bioscience), which is heavily marketed to improve memory.

Med Lett Drugs Ther. 2021 Nov 1; 63(1636):175-6
A synthetic form of the protein apoaequorin is the active ingredient in the over-the-counter dietary supplement Prevagen (Quincy Bioscience), which is heavily marketed to improve memory.
Issue 1626 · June 14, 2021
Drugs for Chronic Heart Failure

Among patients with chronic heart failure, those with a left ventricular ejection fraction (LVEF) ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF). Patients with a LVEF ≥50%…

Med Lett Drugs Ther. 2021 Jun 14; 63(1626):89-96
Among patients with chronic heart failure, those with a left ventricular ejection fraction (LVEF) ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF). Patients with a LVEF ≥50% are considered to have heart failure with preserved ejection fraction (HFpEF). Those with a LVEF of 41-49% are an intermediate group more similar to patients with HFpEF.
Issue 1623 · May 3, 2021 Free
In Brief: Sacubitril/Valsartan (Entresto) Expanded Indication

The oral fixed-dose combination of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan ( Entresto – Novartis) was approved in 2015 to reduce the risk of cardiovascular…

Med Lett Drugs Ther. 2021 May 3; 63(1623):65
The oral fixed-dose combination of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan ( Entresto – Novartis) was approved in 2015 to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction (HFrEF; LVEF <40%). The FDA has now expanded its indication to include patients with chronic heart failure with any LVEF; the label specifies that benefits are most clearly evident in patients with LVEF below normal. Entresto is the first drug to be approved in the US for this indication.
Issue 1619 · March 8, 2021
Vericiguat (Verquvo) for Heart Failure

The FDA has approved vericiguat ( Verquvo – Merck), an oral soluble guanylate cyclase (sGC) stimulator, to reduce the risk of hospitalization for heart failure and cardiovascular (CV) death following a…

Med Lett Drugs Ther. 2021 Mar 8; 63(1619):36-7
The FDA has approved vericiguat ( Verquvo – Merck), an oral soluble guanylate cyclase (sGC) stimulator, to reduce the risk of hospitalization for heart failure and cardiovascular (CV) death following a worsening heart failure event (hospitalization for heart failure or treatment with IV diuretics as an outpatient) in patients with symptomatic chronic heart failure and left ventricular ejection fraction (LVEF) <45%. Vericiguat is the second sGC stimulator to be marketed in the US. Riociguat (Adempas) , which is FDA-approved for treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, was the first.
Issue 1619 · March 8, 2021
Comparison Table: Some Drugs for HFrEF (online only)

View the Comparison Table: Some Drugs for HFrEF

Med Lett Drugs Ther. 2021 Mar 8; 63(1619):e1-14
View the Comparison Table: Some Drugs for HFrEF
Issue 1611 · November 16, 2020
Empagliflozin (Jardiance) for Heart Failure

In a randomized, placebo-controlled trial, the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin ( Jardiance – Boehringer Ingelheim/Lilly) reduced the composite risk of cardiovascular death or…

Med Lett Drugs Ther. 2020 Nov 16; 62(1611):177-8
In a randomized, placebo-controlled trial, the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin ( Jardiance – Boehringer Ingelheim/Lilly) reduced the composite risk of cardiovascular death or hospitalization for worsening heart failure (HF) in patients with heart failure with reduced ejection fraction (HFrEF), whether or not they had type 2 diabetes. To date, empagliflozin has not been approved by the FDA for such use. The SGLT2 inhibitor dapagliflozin (Farxiga) was approved by the FDA for this indication earlier this year.
Issue 1598 · May 18, 2020
Drugs for Hypertension

Drugs available for treatment of chronic hypertension and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed here.

Med Lett Drugs Ther. 2020 May 18; 62(1598):73-80
Drugs available for treatment of chronic hypertension and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed here.
Issue 1575 · July 1, 2019 Free
Correction: Drugs for Chronic Heart Failure

In our Drugs for Chronic Heart Failure article, 1 our description of the PARADIGM-HF trial comparing the combination of the ARB valsartan and the neprilysin inhibitor sacubitril (Entresto) with the ACE…

Med Lett Drugs Ther. 2019 Jul 1; 61(1575):104
In our Drugs for Chronic Heart Failure article, 1 our description of the PARADIGM-HF trial comparing the combination of the ARB valsartan and the neprilysin inhibitor sacubitril (Entresto) with the ACE inhibitor enalapril for treatment of heart failure with reduced ejection fraction (HFrEF) characterized the dosage of enalapril as "suboptimal". Some readers have objected to that characterization. The FDA-approved dosage of enalapril for treatment of HFrEF is 2.5-20 mg twice daily. In PARADIGM-HF, the dosage was capped at 10 mg twice daily, a widely used dosage that has been shown to reduce mortality in patients with HFrEF. 2 In the trial, the rate of death from cardiovascular causes or hospitalization for heart failure was significantly lower with the combination of valsartan and sacubitril than with enalapril 10 mg twice daily (21.8% vs 26.5%). Whether allowing titration to 20 mg twice daily would have changed that result is a reasonable question, but there is no direct evidence that the higher dosage is more effective for this indication. 3 We have removed the word "suboptimal" from the article as it appears online. Med Lett Drugs Ther 2019; 61:49. JJ McMurray et al. N Engl J Med 2014; 371:993. N Bartell and WH Frishman. Cardiol Rev 2017; 25:315. Download complete U.S. English article
Issue 1569 · April 8, 2019
Drugs for Chronic Heart Failure

Patients with a left ventricular ejection fraction (LVEF) ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF). Patients with a LVEF ≤50% and symptoms of heart failure are…

Med Lett Drugs Ther. 2019 Apr 8; 61(1569):49-54
Patients with a left ventricular ejection fraction (LVEF) ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF). Patients with a LVEF ≤50% and symptoms of heart failure are considered to have heart failure with preserved ejection fraction (HFpEF). There is little evidence that drug treatment improves clinical outcomes in patients with HFpEF.
Issue 1569 · April 8, 2019
Expanded Table: Some Drugs for HFrEF (online only)

View the Expanded Table: Some Drugs for HFrEF

Med Lett Drugs Ther. 2019 Apr 8; 61(1569):e57-62
View the Expanded Table: Some Drugs for HFrEF
Issue 1516 · March 13, 2017
Drugs for Hypertension

in the US and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed here.

Med Lett Drugs Ther. 2017 Mar 13; 59(1516):41-8
in the US and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed here.
Issue 1503 · September 12, 2016
Byvalson - A Beta Blocker/ARB Combination for Hypertension

The FDA has approved Byvalson (Allergan), a fixed-dose combination of the beta blocker nebivolol (Bystolic) and the angiotensin receptor blocker (ARB) valsartan ( Diovan , and generics), for treatment of…

Med Lett Drugs Ther. 2016 Sep 12; 58(1503):115-7
The FDA has approved Byvalson (Allergan), a fixed-dose combination of the beta blocker nebivolol (Bystolic) and the angiotensin receptor blocker (ARB) valsartan ( Diovan , and generics), for treatment of hypertension. It is the only combination product that contains nebivolol, and the first to combine a beta blocker with an ARB.
Issue 1474 · August 3, 2015
Sacubitril/Valsartan (Entresto) for Heart Failure

The FDA has approved Entresto (Novartis), an oral fixed-dose combination of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan, to reduce the risk of cardiovascular death…

Med Lett Drugs Ther. 2015 Aug 3; 57(1474):107-9
The FDA has approved Entresto (Novartis), an oral fixed-dose combination of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan, to reduce the risk of cardiovascular death and heart failure hospitalization in patients with heart failure with reduced ejection fraction. Sacubitril is the first neprilysin inhibitor to become available in the US.
Issue 1473 · July 20, 2015
Prestalia - Another Combination for Hypertension

The FDA has approved Prestalia (Symplmed), an oral fixed-dose combination of the dihydropyridine calcium channel blocker amlodipine ( Norvasc , and generics) and a new salt form of the angiotensin-converting…

Med Lett Drugs Ther. 2015 Jul 20; 57(1473):103-4
The FDA has approved Prestalia (Symplmed), an oral fixed-dose combination of the dihydropyridine calcium channel blocker amlodipine ( Norvasc , and generics) and a new salt form of the angiotensin-converting enzyme (ACE) inhibitor perindopril, for treatment of hypertension in patients not adequately controlled on monotherapy or already taking both drugs, and in those just starting therapy who are likely to need multiple drugs to control their blood pressure. The new salt form (perindopril arginine) is more stable and has a longer shelf-life than perindopril erbumine ( Aceon , and generics). Two other ACE inhibitor/calcium channel blocker combinations, benazepril/amlodipine ( Lotrel , and generics) and trandolapril/verapamil ER ( Tarka , and generics), have been available in the US for many years.
Issue 1460 · January 19, 2015
Drugs for Chronic Heart Failure

Heart failure is usually associated with left ventricular dysfunction. According to recent guidelines, patients with a left ventricular ejection fraction (LVEF) ≤40% are considered to have heart failure with…

Med Lett Drugs Ther. 2015 Jan 19; 57(1460):9-13
Heart failure is usually associated with left ventricular dysfunction. According to recent guidelines, patients with a left ventricular ejection fraction (LVEF) ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF) or systolic heart failure. Patients with a LVEF ≥50% and symptoms of heart failure are considered to have heart failure with preserved ejection fraction (HFpEF) or diastolic heart failure; there is little evidence that drug treatment improves clinical outcomes in these patients. The treatment of acute heart failure is not included here.
Issue 121 · September 1, 2012
Drugs for Chronic Heart Failure

Chronic systolic heart failure is usually associated with a left ventricular ejection fraction (LVEF) of ≤40%. Many patients with symptoms of heart failure have higher ejection fractions, but there is no…

Treat Guidel Med Lett. 2012 Sep; 10(121):69-72
Chronic systolic heart failure is usually associated with a left ventricular ejection fraction (LVEF) of ≤40%. Many patients with symptoms of heart failure have higher ejection fractions, but there is no evidence that drug treatment of heart failure with preserved systolic function (LVEF >40%) improves clinical outcomes. Some of the drugs commonly used now for treatment of chronic heart failure are listed in the table on page 71.
Issue 1385 · March 5, 2012
Edarbyclor: An ARB/Chlorthalidone Combination for Hypertension

The FDA has approved a fixed-dose combination of the angiotensin receptor blocker (ARB) azilsartan and the thiazide-like diuretic chlorthalidone as Edarbyclor (Takeda) for treatment of hypertension

Med Lett Drugs Ther. 2012 Mar 5; 54(1385):17-8
The FDA has approved a fixed-dose combination of the angiotensin receptor blocker (ARB) azilsartan and the thiazide-like diuretic chlorthalidone as Edarbyclor (Takeda) for treatment of hypertension
Issue 113 · January 1, 2012
Drugs for Hypertension

Drugs available in the US for treatment of chronic hypertension, with their dosages and adverse effects, are listed in the tables that begin on page 2. Combination products are listed on page 8. Drugs for…

Treat Guidel Med Lett. 2012 Jan; 10(113):1-10
Drugs available in the US for treatment of chronic hypertension, with their dosages and adverse effects, are listed in the tables that begin on page 2. Combination products are listed on page 8. Drugs for treatment of hypertensive emergencies are not discussed here. They were reviewed previously.
Issue 1364 · May 16, 2011
Azilsartan Medoxomil (Edarbi) - The Eighth ARB

The angiotensin receptor blocker (ARB) azilsartan medoxomil ( Edarbi – Takeda) was recently approved by the FDA for oral treatment of hypertension, either alone or combined with other drugs. It is the eighth…

Med Lett Drugs Ther. 2011 May 16; 53(1364):39-40
The angiotensin receptor blocker (ARB) azilsartan medoxomil ( Edarbi – Takeda) was recently approved by the FDA for oral treatment of hypertension, either alone or combined with other drugs. It is the eighth ARB approved for this indication.
Issue 1361 · April 4, 2011 Free
In Brief: Another Three-Drug Combination for Hypertension

The FDA has approved aliskiren/amlodipine/hydrochlorothiazide (Amturnide) for treatment of hypertension, with no restrictions except that it should not be used for initial therapy. A combination of the direct…

Med Lett Drugs Ther. 2011 Apr 4; 53(1361):28
The FDA has approved aliskiren/amlodipine/hydrochlorothiazide (Amturnide) for treatment of hypertension, with no restrictions except that it should not be used for initial therapy. A combination of the direct renin inhibitor aliskiren and the calcium channel blocker amlodipine (Tekamlo) was approved earlier for initial treatment. 1 Use of combination tablets is, of course, more convenient than taking the components separately, and as long as all the same doses are available and the cost is no greater, there is no reason not to use them. Aliskiren alone or in combination has not been shown to improve clinical outcomes. 2 Whether it offers any advantage over the angiotensin receptor blockers (ARBs), which are also available in various antihypertensive combinations, remains to be determined. 1. Aliskiren/amlodipine (Tekamlo): another combination tablet for hypertension. Med Lett Drugs Ther 2010; 52:94. 2. Drugs for hypertension. Treat Guidel Med Lett 2009; 7:1. Download U.S. English
Issue 1346 · September 6, 2010
Tribenzor for Hypertension

Many patients with hypertension require more than one drug to control their blood pressure. Tribenzor (Daiichi Sankyo), recently approved by the FDA for treatment of hypertension, combines the calcium channel…

Med Lett Drugs Ther. 2010 Sep 6; 52(1346):70-1
Many patients with hypertension require more than one drug to control their blood pressure. Tribenzor (Daiichi Sankyo), recently approved by the FDA for treatment of hypertension, combines the calcium channel blocker amlodipine ( Norvasc , and others), the angiotensin receptor blocker (ARB) olmesartan (Benicar) and the most commonly prescribed diuretic, hydrochlorothiazide (HCTZ). Tribenzor is not approved for initial therapy, but is recommended for patients not adequately controlled on any 2-drug combination of a calcium channel blocker, an ARB or a diuretic.
Issue 1329 · January 11, 2010
A Third Amlodipine/ARB Combination (Twynsta) for Hypertension

The FDA has approved Twynsta (Boehringer Ingelheim), a fixed-dose combination of the calcium-channel blocker (CCB) amlodipine and the angiotensin receptor blocker (ARB) telmisartan, for treatment of…

Med Lett Drugs Ther. 2010 Jan 11; 52(1329):2-3
The FDA has approved Twynsta (Boehringer Ingelheim), a fixed-dose combination of the calcium-channel blocker (CCB) amlodipine and the angiotensin receptor blocker (ARB) telmisartan, for treatment of hypertension.
Issue 1326 · November 30, 2009
Aliskiren/Valsartan (Valturna) for Hypertension

The FDA has approved the use of aliskiren (Tekturna) , a direct renin inhibitor, with valsartan (Diovan) , an angiotensin-receptor blocker (ARB), in a fixed-dose combination as Valturna (Novartis) for…

Med Lett Drugs Ther. 2009 Nov 30; 51(1326):94-5
The FDA has approved the use of aliskiren (Tekturna) , a direct renin inhibitor, with valsartan (Diovan) , an angiotensin-receptor blocker (ARB), in a fixed-dose combination as Valturna (Novartis) for treatment of hypertension in patients already taking both drugs or not adequately controlled on monotherapy, and as initial therapy in those likely to need multiple drugs to control their blood pressure.
Issue 83 · July 1, 2009
Drugs for Treatment of Chronic Heart Failure

The range of drugs for treatment of chronic heart failure continues to expand. Some of those commonly used now are listed in the table on page 55. Mechanical therapies for the treatment of heart failure such…

Treat Guidel Med Lett. 2009 Jul; 7(83):53-6
The range of drugs for treatment of chronic heart failure continues to expand. Some of those commonly used now are listed in the table on page 55. Mechanical therapies for the treatment of heart failure such as cardiac resynchronization, implanted cardiac defibrillators (ICDs), ventricular assist devices and ultrafiltration for the relief of congestion will not be reviewed here.
Issue 1314 · June 15, 2009
Exforge HCT

Most patients with hypertension require more than one drug to control their blood pressure. Exforge HCT (Novartis) is a new 3-drug fixed-dose combination tablet approved by the FDA for treatment of…

Med Lett Drugs Ther. 2009 Jun 15; 51(1314):46
Most patients with hypertension require more than one drug to control their blood pressure. Exforge HCT (Novartis) is a new 3-drug fixed-dose combination tablet approved by the FDA for treatment of hypertension. It combines the calcium-channel blocker amlodipine ( Norvasc , and others) and the angiotensin receptor blocker (ARB) valsartan (Diovan) , which are already available in a combination tablet (Exforge) , with the most commonly prescribed diuretic hydrochlorothiazide (HCTZ). Exforge HCT is not approved for initial treatment of hypertension, but rather for patients not adequately controlled on a 2-drug combination of a calcium-channel blocker, an ARB or a diuretic. It can also be substituted for amlodipine, valsartan and HCTZ in patients already taking all 3 of these drugs.
Issue 77 · January 1, 2009
Drugs for Hypertension

Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 2. Combination products are listed on page 9. Drugs…

Treat Guidel Med Lett. 2009 Jan; 7(77):1-10
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 2. Combination products are listed on page 9. Drugs for treatment of hypertensive emergencies are not discussed here. They were reviewed in Treatment Guidelines ( volume 1, page 19, December 2002 ) and in The Medical Letter ( volume 50, page 73, September 22, 2008 ).
Issue 1293 · August 25, 2008
Aliskiren/Hydrochlorothiazide (Tekturna HCT) for Hypertension

Aliskiren ( Tekturna - Novartis), the first direct renin inhibitor for treatment of hypertension, has been approved for use in a fixed-dose combination with the diuretic hydrochlorothiazide ( Tekturna HCT -…

Med Lett Drugs Ther. 2008 Aug 25; 50(1293):65-6
Aliskiren ( Tekturna - Novartis), the first direct renin inhibitor for treatment of hypertension, has been approved for use in a fixed-dose combination with the diuretic hydrochlorothiazide ( Tekturna HCT - Novartis). Many angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are also available in fixed-dose combinations with hydrochlorothiazide (HCTZ).
Issue 1276 · December 17, 2007
Two Amlodipine/ARB Combinations for Hypertension

The FDA has approved Exforge (Novartis) and Azor (Daiichi Sankyo), the first combinations of a calcium channel blocker (CCB) with an angiotensin receptor blocker (ARB) for treatment of hypertension. Amlodipine…

Med Lett Drugs Ther. 2007 Dec 17; 49(1276):101-2
The FDA has approved Exforge (Novartis) and Azor (Daiichi Sankyo), the first combinations of a calcium channel blocker (CCB) with an angiotensin receptor blocker (ARB) for treatment of hypertension. Amlodipine is the CCB in both products. The ARBs are valsartan in Exforge and olmesartan in Azor. All 3 of these drugs are available in fixed-dose combinations with other antihypertensive drugs.
Issue 41 · January 1, 2006
Drugs for Treatment of Heart Failure

The choice of drugs for treatment of chronic heart failure continues to evolve. Those most commonly used now are listed in the table on page 3. The use of implanted cardiac defibrillators (ICDs) to reduce the…

Treat Guidel Med Lett. 2006 Jan; 4(41):1-4
The choice of drugs for treatment of chronic heart failure continues to evolve. Those most commonly used now are listed in the table on page 3. The use of implanted cardiac defibrillators (ICDs) to reduce the incidence of sudden death in patients with heart failure and the treatment of decompensated heart failure were discussed in previous issues.
Issue 34 · June 1, 2005
Drugs for Hypertension

Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 40. Combination products are listed on page 47. Drugs…

Treat Guidel Med Lett. 2005 Jun; 3(34):39-48
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 40. Combination products are listed on page 47. Drugs for treatment of hypertensive emergencies are not discussed here.
Issue 1208 · May 9, 2005
ARBs and Myocardial Infarction

Angiotensin receptor blockers (ARBs) are widely used as an alternative to angiotensin converting enzyme (ACE) inhibitors for treatment of hypertension because they lower blood pressure without inducing a…

Med Lett Drugs Ther. 2005 May 9; 47(1208):38-9
Angiotensin receptor blockers (ARBs) are widely used as an alternative to angiotensin converting enzyme (ACE) inhibitors for treatment of hypertension because they lower blood pressure without inducing a cough. It has not been established that they provide the same cardiac benefits as ACE inhibitors. Recently, an editorial in the British Medical Journal suggested that ARBs may increase the risk of myocardial infarction.
Issue 1186 · July 5, 2004
Initial Therapy of Hypertension

The importance of adequate control of hypertension in preventing organ damage and death is well established, but the choice of drugs is still controversial. Three recent drug trials, one supporting initial…

Med Lett Drugs Ther. 2004 Jul 5; 46(1186):53-5
The importance of adequate control of hypertension in preventing organ damage and death is well established, but the choice of drugs is still controversial. Three recent drug trials, one supporting initial therapy with a diuretic, the second favoring an angiotensin converting enzyme (ACE) inhibitor, and the third showing equivalence between a calcium-channel blocker and an angiotensin-receptor blocker (ARB) have intensified the debate.
Issue 8 · April 1, 2003
Drugs for Treatment of Heart Failure

The choice of drugs for treatment of chronic heart failure continues to evolve. It has become increasingly recognized that drugs used in heart failure produce beneficial effects through neurohormonal as well…

Treat Guidel Med Lett. 2003 Apr; 1(8):53-6
The choice of drugs for treatment of chronic heart failure continues to evolve. It has become increasingly recognized that drugs used in heart failure produce beneficial effects through neurohormonal as well as hemodynamic mechanisms. The treatment of decompensated heart failure is not discussed here; drugs used for this indication were reviewed in Cardiovascular Drugs in the ICU, Treatment Guidelines from The Medical Letter 2002; 1:19 .
Issue 6 · February 1, 2003
Drugs for Hypertension

Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the table that begins on page 35. Combination products are listed on page 39. Drugs…

Treat Guidel Med Lett. 2003 Feb; 1(6):33-40
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the table that begins on page 35. Combination products are listed on page 39. Drugs for treatment of hypertensive emergencies were discussed in Treatment Guidelines volume 1, issue 4, page 19, December 2002.
Issue 1099 · March 5, 2001
Drugs for Hypertension

Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the text.

Med Lett Drugs Ther. 2001 Mar 5; 43(1099):17-22
Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the text.
Issue 1065 · November 5, 1999
A New Ace Inhibitor and Two New Angiotensin Receptor Blockers For Hypertension

Perindopril, the tenth angiotensin converting enzyme (ACE) inhibitor to be marketed in the USA, and telmisartan and eprosartan, the fifth and sixth angiotensin receptor blockers, have recently become available…

Med Lett Drugs Ther. 1999 Nov 5; 41(1065):105-6
Perindopril, the tenth angiotensin converting enzyme (ACE) inhibitor to be marketed in the USA, and telmisartan and eprosartan, the fifth and sixth angiotensin receptor blockers, have recently become available for treatment of hypertension.
Issue 1048 · March 12, 1999
Drugs for Hypertension

Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the text.

Med Lett Drugs Ther. 1999 Mar 12; 41(1048):23-8
Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the text.
Issue 1045 · January 29, 1999
Drugs for Chronic Heart Failure

The choice of drugs for treatment of heart failure depends on both hemodynamic and neurohormonal factors.

Med Lett Drugs Ther. 1999 Jan 29; 41(1045):12-4
The choice of drugs for treatment of heart failure depends on both hemodynamic and neurohormonal factors.
Issue 1040 · November 20, 1998
Candesartan for Hypertension

Candesartan cilexetil ( Atacand - Astra) is the fourth angiotensin II receptor antagonist to become available in the USA for oral treatment of hypertension.

Med Lett Drugs Ther. 1998 Nov 20; 40(1040):109-10
Candesartan cilexetil ( Atacand - Astra) is the fourth angiotensin II receptor antagonist to become available in the USA for oral treatment of hypertension.
Issue 1019 · January 30, 1998
Irbesartan for Hypertension

Irbesartan ( Avapro - Sanofi/Bristol-Myers Squibb) is the third angiotensin II receptor antagonist to become available in the USA for oral treatment of hypertension. Losartan (Cozaar) and valsartan (Diovan)…

Med Lett Drugs Ther. 1998 Jan 30; 40(1019):18-9
Irbesartan ( Avapro - Sanofi/Bristol-Myers Squibb) is the third angiotensin II receptor antagonist to become available in the USA for oral treatment of hypertension. Losartan (Cozaar) and valsartan (Diovan) were marketed earlier. Eprosartan ( Teveten - SmithKline Beecham) has been approved by the FDA but not marketed.